Fiche société
Viatris Pharmaceuticals Co., Ltd.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Cenerimod 4 mgThe purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE). | Lupus | Phase 2 | À vérifier | China | À vérifier |
| Cenerimod 4 mgThe purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE). | Lupus | Phase 2 | À vérifier | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Cenerimod 4 mg | Lupus | Phase 2 | NCT07266090 | A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE) | ACTIVE_NOT_RECRUITING |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Cenerimod 4 mg | First use of cenerimod, a selective S1P receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. | Lupus science & medicine | ||
| Cenerimod 4 mg | Lack of Effect of Cenerimod, a Selective S1P Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive. | International journal of molecular sciences |